Neuromuscular Blocking Agents Flashcards

1
Q

Under which category does the neuromuscular blockers fall under?

A

Somatic Nervous System under the Peripheral Nervous System

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Somatic Fiber ?

A

-Has no ganglia, indirectly innervates muscle
-Has nicotonic receptor
-Has Ach as a neurotransmitter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Neuromuscular Junction?

A

Synapse between presynaptic motor neuron and postsynapatic muscle membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

General anethesia?

A

Includes analgesia, amnesia, loss of consciousness, inhibition of sensory and automatic reflexes and skeletal muscle relaxtion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Where are neuromuscular blockers used?

A

Used in anaesthesia and artificial ventilation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Somatic Nervous System innervation?

A

Skin, sensory, organs and skeletal muscle-transmits information from CNS to the rest of the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Two major neuron types?

A

*Sensory neurons (afferent
neurons): body -CNS

*Motor neurons (efferent
neurons): brain and
spinal cord muscle
fibers throughout the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Normal neuromuscular transmission?

A
  1. Action potential (AP) conducted along the motor neuron
  2. Depolarization
  3. Ca2+ influx
  4. ACh release from storage vesicles into a synaptic cleft
  5. ACh binds on nicotinic receptors on the motor end plate
  6. Na+ channels on motor end plate open
  7. Na+ influx and depolarization (end plate potential (EPP))
  8. AP produced
  9. Muscle contraction occurs
  10. ACh hydrolyzed by AChE from motor end plate and process starts again
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which step of neuromuscular transmission do neuromuscular blockers ?

A

Step 5
5. ACh binds on nicotinic receptors on the motor end plate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Skeletal Muscle Relaxtants types?

A
  1. Peripherally-acting agents
    -Depolarising NMBD’S
    -Nondepolarising NMBDs
  2. Centrally-acting agents
    -act on the CNS
  3. Directly-acting agents
    -act on the muscle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Structure of NMBD’S?

A

Structurally polar-do not cross blood brain barrier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

NMD administration?

A

All administered parenterally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

NMD action?

A

Relax voluntary skeletal muscles, diaphragm and laryngeal muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

General MOA of NMB?

A

structurally similar to ACh
act at the post-junction nicotinic receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

NMB agonists or antagonists?

A

*agonists = depolarizing NMBDs
mimic ACh
persisting state of depolarization

*antagonists = non-depolarizing NMBDs
competitive inhibitors of ACh
prevent depolarization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Types of Peripherally acting NMB?

A
  1. Depolarizing NMBDs
  2. Non-depolarizing NMBDs
    Can be identified by “cur”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

NMB Depolarising drugs?

A

*Succinylcholine (suxamethonium)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

NMB non-depolarising drugs types?

A

a) Isoquinoline derivatives

b) Steroid derivatives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

NMB Isoquinoline derivative drugs?

A

MAD

*Mivacurium
*Atracurium
*d-tubocurarine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

NMB Steroid derivatives drugs?

A

Very Running People

Vecuronium
Rocuronium
Pancuronium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Succinylcholine MOA?

A

only depolarizing NMBD in clinical use
causes ↑ EPP rapid muscle contraction,
clinically observed as muscle fasciculation
this is followed by flaccid paralysis within 30-
60 sec and lasts for 3-5 min
with repeated dose, receptors reach
tolerance rapid and complete muscle
relaxation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Succinylcholine (SCh) phases?

A

Phase I

ACh agonist
triggers EPP via the ACh cascade
Voltage-gated Na+ channels open depolarization
increase Ca2+ release from sarcoplasmic reticulum
rapid muscle contraction (muscle fasciculations/twitches)
followed by muscle relaxation (flaccid paralysis)

Phase II

continued SCh exposure (repeated doses)
Na+ channels non-responsive to the stimulus repolarization
rapid and complete muscle relaxation

23
Q

How long does the phase one of Succinylcholine ?

A

lasts for 3-5 min

24
Q

Succinylcholine hyrolysed by?

A

not hydrolyzed by AChE)

Hydrolysed by plasma pseudocholinesterase

25
Succinylcholine duration?
resolves spontaneously within 10 minutes
26
Succinylcholine P/K? M & E
Metabolism: liver (CYP450), plasma (pseudocholinesterases) *Excretion: renal, only 10% excreted unchanged
27
Succinylcholine DI?
*Cholinesterase inhibitors *Digoxin
28
Succinylcholine A/E?
*Malignant hyperthermia *myalgia *Bradycardia *Hypotension *Increased IOP *Increased intragastric pressure *Increased salivation
29
Succinylcholine stimulate which othe receptors and what is their effects?
Stimulation of autonomic muscarinic receptors bradycardia Hypotension Increased salivation
30
What is the solution to succinylcholine to avoid muscuranic effects?
Atropine prior to repeated doses or continuous infusion of SCh to counteract these effects competitively antagonize muscarinic activity prevent bradycardia and hypotension
31
Nondepolarizing NMBDs MOA?
competitively antagonize ACh prevent EPP prevent Ca2+ release from sarcoplasmic reticulum muscle relaxation
32
Nondepolarizing Irr/reversible?
Reversible
33
Nondepolarizing Administeration?
All administered IV They do not cross the placenta and BBB
34
Tubocuraine?
Tubocurarine is a toxic alkaloid from curare historically known for its use as an arrow poison. a prototype from which many synthetic nondepolarizing NMBDs were synthesized rarely used in clinical medicine
35
What do non-depolarising drugs release and what is the exception?
Most nondepolarizing NMBDs (except rocuronium) release histamine and exhibit histamine-related side effects
36
What are histamine S/E?
Hypotension Bronchospasm
37
Non-depolarising duration?
Short acting: Mivacurium("Move Mivacurium) Intermediate-acting: Really Very Aware Rocuronium Vecuronium Atracurium Long-acting: Paced DRugs Pancuronium d-tubocurarine
38
Which non-depolarising NMB is the most rapid onset of action?
Rocuronium
39
Which non-depolarising NMB is the most slowest but has the longest duration?
Pancuronium
40
Which non-depolarising NMB is the most potent in releasing histamine?
Mivacuronium
41
Mivacuronium metabolism?
Plasma cholinesterase
42
Mivacuronium S/E?
Bronchospasm, Hypotension, prolonged neuromuscular blocker
43
Atracurium P/K? M, E & DI
M: spontaneous (Hoffman) degradation at body temp. and pH  Drug of choice in liver failure E: renal mainly DI: incompatible with thiopental sodium (used in GA induction phase)
44
Vecuronium P/K? M& E
M: liver E: bile mainly
45
Vecuronium S/E?
Bronchospasm, Anaphylaxis
46
Rocuronium P/K? M, E & DI
M: liver E: bile DI: Phenytoin, carbamazepine may cause recovery
47
Rocuronium S/E?
Anaphylaxis
48
Tubocurarine P/K? M & E
M: Hoffman degradation and hepatic E: renal mainly
49
Tubocurarine S/E?
Hypotension, bronchospasm
50
Pancuronium P/K? M&E
M: liver (small amount) E: renally mainly unchanged
51
Pancuronium S/E?
Tachycardia, elevation in BP
52
NMJ Blockade reversal?
Acetycholinesterase iNhibitors Eg:Neostigmine
53
NMJ Blockade reversal action?
1. block ACh hydrolysis 2. accumulation of ACh 3. NMJ blocker displacement
54
What antimuscuranic agent may need to be used to block musarinic effects?
Antimuscarinic agent, atropine, may need to be concurrently used to block the muscarinic effects of ACh i.e. bradycardia